Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

BACKGROUND: Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs). We report efficacy and safety results of vatalanib in advanced gastrointestinal stromal tumour (GIST) r...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Joensuu, H, De Braud, F, Grignagni, G, De Pas, T, Spitalieri, G, Coco, P, Spreafico, C, Boselli, S, Toffalorio, F, Bono, P, Jalava, T, Kappeler, C, Aglietta, M, Laurent, D, Casali, P G
格式: Artigo
語言:Inglês
出版: Nature Publishing Group 2011
主題:
Clinical Study
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3111164/
https://ncbi.nlm.nih.gov/pubmed/21540861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.151
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍